GemPharmatech Presents Humanized Mouse Models to Support Bispecific Antibody and COVID-19 Preclinic Development at Biologics UK Oxford Global Conference

WILMINGTON, Del.--(BUSINESS WIRE)--GemPharmatech (GemPharmatech Co., Ltd. “GPT”) presented its humanized mouse models to support T-Cell Bispecific antibody and COVID-19 preclinic development and co-hosted a panel discussion on bispecific antibodies at Biologics UK Oxford Global Conference, London, UK, Sept. 6-8, 2021. The conference is the biggest in-person biologics event in London and was attended by hundreds of industrial and academic researchers and business partners from around the globe.

Biologics have emerged as novel and effective therapeutics against many types of diseases, especially in the field of immuno-oncology. As the potential applications of biologics continue to grow, so does the need for the proper animal models to use for preclinical studies. GemPharmatech is a leading global provider of animal models and services, especially in generating genetically engineered mouse models for preclinical research and development. Since 2017, GPT has created a collection of more than 17,000 animal models. GPT has established partnerships in the US to allow shorter shipping time and lower cost and enables GPT to provide animal models and related services faster and closer to its customers in the R&D communities, which include large pharmaceutical and Biotech companies, contract research organizations (CROs), universities, and research institutions throughout the US.

“Humanized mouse models provide very valuable tools for supporting pre-clinical studies,” said Dr. Moore, President and CEO of GemPharmatech LLC, a US subsidiary of GemPharmatech Co., Ltd. “In our presentation and panel discussion at the conference, we specifically outlined the applications of our humanized mouse models in supporting the development of bispecific antibodies and our ACE2 lines that are important systems for identifying antibodies, therapeutics and understanding the pathogenesis and treatment of COVID-19. In addition, we have produced a large collection of humanized mouse models including over 80 humanized immune checkpoint models, as well as the CD3e mouse models that can be used in a wide range of preclinical discovery and developmental studies,” continued Dr. Moore.

About GemPharmatech

GemPharmatech, Co., Ltd. (GPT) is a leading provider in animal models and services, especially in the development of humanized animal models, to global Pre-Clinical R&D Communities. The Company is specialized in developing animal models using cutting edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficiency mice and Germfree mice. GemPharmatech provides a one-stop service as model customization, breeding, phenotyping, and pharmacology services including drug efficacy test and mouse phenotyping, CRISPR/Cas9 gene-editing, ES HR, transgenic, cryopreservation, assisted reproduction, rapid expansion and derivatives and customized breeding. The company has developed one of the world's largest mouse strain resources to inspire scientific innovation and accelerate drug discovery. GemPharmatech LLC is a wholly owned US subsidiary of GemPharmatech, Co., Ltd., located in Wilmington, Delaware. Visit https://www.gempharmatech.us for details.

Media:
Gann Xu, Ph. D.
Executive Director
GemPharmatech LLC
Tel: 888 899 5899
Email: Gann.Xu@GemPharmatech.us